Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models

Journal of Virology

Volumn 84, Issue 2, 2010, Pages 856-866

  Guse, Kilian ^a,b   Sloniecka, Marta ^a,b   Diaconu, Iulia ^a,b   Ottolino Perry, Kathryn ^c   Tang, Nan ^c   Ng, Calvin ^c   Le Boeuf, Fabrice ^d   Bell, John C ^d   McCart, J Andrea ^c   Ristimäki, Ari ^b,e,f   Pesonen, Sari ^a,b   Cerullo, Vincenzo ^a,b   Hemminki, Akseli ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY OF HELSINKI   (Finland)

^f UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ONCOLYTIC VIRUS; ONCOLYTIC VIRUS VVDD VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 PROTEIN IG; THYMIDINE KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MODEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; EXTRAMEDULLARY HEMATOPOIESIS; GENE DELETION; GENE TRANSFER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; INNATE IMMUNITY; KIDNEY CANCER; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; TUMOR VASCULARIZATION; VACCINIA VIRUS; VIROGENESIS; VIRUS REPLICATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED HOST; KIDNEY; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; THYMIDINE KINASE; TREATMENT OUTCOME; VACCINIA VIRUS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

MUS; VACCINIA VIRUS;

EID: 73849126308     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00692-09     Document Type: Article

References (47)

1. Adler, S. P., and B. Marshall. 2007. Cytomegalovirus infections. Pediatr. Rev. 28:92-100.
2. Brunetti-Pierri, N., D. J. Palmer, A. L. Beaudet, K. D. Carey, M. Finegold, and P. Ng. 2004. Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum. Gene Ther. 15:35-46.
3. Buller, R. M., S. Chakrabarti, J. A. Cooper, D. R. Twardzik, and B. Moss. 1988. Deletion of the vaccinia virus growth factor gene reduces virus virulence. J. Virol. 62:866-874.
4. Buller, R. M., and G. J. Palumbo. 1991. Poxvirus pathogenesis. Microbiol. Rev. 55:80-122.
5. Buller, R. M., G. L. Smith, K. Cremer, A. L. Notkins, and B. Moss. 1985. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 317:813-815.
6. Chakrabarti, S., J. R. Sisler, and B. Moss. 1997. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 23:1094-1097.
7. Chowdhury, S., J. M. Larkin, and M. E. Gore. 2008. Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies. Eur. J. Cancer 44:2152-2161.
8. Condit, R. C. 2007. Principles of virology, p. 38-40. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 5th ed., vol. 1. Lippincott Williams & Wilkins, Philadelphia, PA.
9. Coppin, C., F. Porzsolt, A. Awa, J. Kumpf, A. Coldman, and T. Wilt. 2005. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. 2005(1):CD001425.
10. Earl, P. L., B. Moss, L. S. Wyatt, and M. W. Carroll. 1998. Preparation of cell cultures and vaccinia virus stocks, p. 16.17.1-16.17.19. Current protocols in molecular biology, vol. 2. Greene Publishing Associates and Wiley Interscience, New York, NY.
11. Ellis, L. M., and D. J. Hicklin. 2008. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 8:579-591.
12. Eskens, F. A., and J. Verweij. 2006. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors a review. Eur. J. Cancer 42:3127-3139.
13. Ferrara, N. 1999. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int. 56:794-814.
14. Foloppe, J., J. Kintz, N. Futin, A. Findeli, P. Cordier, Y. Schlesinger, C. Hoffmann, C. Tosch, J. M. Balloul, and P. Erbs. 2008. Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus. Gene Ther. 15:1361-1371.
15. George, B. A., X. J. Zhou, and R. Toto. 2007. Nephrotic syndrome after bevacizumab: case report and literature review. Am. J. Kidney Dis. 49:e23-e29.
16. Gnant, M. F., M. Puhlmann, H. R. Alexander, Jr., and D. L. Bartlett. 1999. Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice. Cancer Res. 59:3396-3403.
17. Godley, P., and S. W. Kim. 2002. Renal cell carcinoma. Curr. Opin. Oncol. 14:280-285.
18. Goldman, C. K., R. L. Kendall, G. Cabrera, L. Soroceanu, Y. Heike, G. Y. Gillespie, G. P. Siegal, X. Mao, A. J. Bett, W. R. Huckle, K. A. Thomas, and D. T. Curiel. 1998. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc. Natl. Acad. Sci. U. S. A. 95:8795-8800.
19. Haviv, Y. S., W. J. van Houdt, B. Lu, D. T. Curiel, and Z. B. Zhu. 2004. Transcriptional targeting in renal cancer cell lines via the human CXCR4 promoter. Mol. Cancer Ther. 3:687-691.
20. Kaelin, W. G., Jr. 2004. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin. Cancer Res. 10:6290S-6295S.
21. Kim, K. J., B. Li, J. Winer, M. Armanini, N. Gillett, H. S. Phillips, and N. Ferrara. 1993. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844.
22. Kirn, D. H., and S. H. Thorne. 2009. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat. Rev. Cancer 9:64-71.
23. Kolb-Maurer, A., and W. Goebel. 2003. Susceptibility of hematopoietic stem cells to pathogens: role in virus/bacteria tropism and pathogenesis. FEMS Microbiol. Lett. 226:203-207.
24. Mahasreshti, P. J., M. Kataram, M. H. Wang, C. R. Stockard, W. E. Grizzle, D. Carey, G. P. Siegal, H. J. Haisma, R. D. Alvarez, and D. T. Curiel. 2003. Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin. Cancer Res. 9:2701-2710.
25. Mahasreshti, P. J., J. G. Navarro, M. Kataram, M. H. Wang, D. Carey, G. P. Siegal, M. N. Barnes, D. M. Nettelbeck, R. D. Alvarez, A. Hemminki, and D. T. Curiel. 2001. Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma. Clin. Cancer Res. 7:2057-2066.
26. Mastrangelo, M. J., H. C. Maguire, Jr., L. C. Eisenlohr, C. E. Laughlin, C. E. Monken, P. A. McCue, A. J. Kovatich, and E. C. Lattime. 1999. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. 6:409-422.
27. McCart, J. A., J. M. Ward, J. Lee, Y. Hu, H. R. Alexander, S. K. Libutti, B. Moss, and D. L. Bartlett. 2001. Systemic cancer therapy with a tumorselective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 61:8751-8757.
28. Naik, A. M., S. Chalikonda, J. A. McCart, H. Xu, Z. S. Guo, G. Langham, D. Gardner, S. Mocellin, A. E. Lokshin, B. Moss, H. R. Alexander, and D. L. Bartlett. 2006. Intravenous and isolated limb perfusion delivery of wild type and a tumor-selective replicating mutant vaccinia virus in nonhuman primates. Hum. Gene Ther. 17:31-45.
29. Nicol, D., S. I. Hii, M. Walsh, B. Teh, L. Thompson, C. Kennett, and D. Gotley. 1997. Vascular endothelial growth factor expression is increased in renal cell carcinoma. J. Urol. 157:1482-1486.
30. O'Connell, J., M. W. Bennett, G. C. O'Sullivan, J. K. Collins, and F. Shanahan. 1999. Fas counter-attack: the best form of tumor defense? Nat. Med. 5:267-268.
31. Olofsson, B., E. Korpelainen, M. S. Pepper, S. J. Mandriota, K. Aase, V. Kumar, Y. Gunji, M. M. Jeltsch, M. Shibuya, K. Alitalo, and U. Eriksson. 1998. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 95:11709-11714.
32. Park, B. H., T. Hwang, T. C. Liu, D. Y. Sze, J. S. Kim, H. C. Kwon, S. Y. Oh, S. Y. Han, J. H. Yoon, S. H. Hong, A. Moon, K. Speth, C. Park, Y. J. Ahn, M. Daneshmand, B. G. Rhee, H. M. Pinedo, J. C. Bell, and D. H. Kirn. 2008. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 9:533-542.
33. Parkin, D. M., F. Bray, J. Ferlay, and P. Pisani. 2005. Global cancer statistics, 2002. CA Cancer J. Clin. 55:74-108.
34. Peplinski, G. R., A. K. Tsung, M. J. Casey, J. B. Meko, T. N. Fredrickson, R. M. Buller, and J. A. Norton. 1996. In vivo murine tumor gene delivery and expression by systemic recombinant vaccinia virus encoding interleukin-1beta. Cancer J. Sci. Am. 2:21-27.
35. Puhlmann, M., M. Gnant, C. K. Brown, H. R. Alexander, and D. L. Bartlett. 1999. Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy. Hum. Gene Ther. 10:649-657.
36. Quigley, M., J. Martinez, X. Huang, and Y. Yang. 2009. A critical role for direct TLR2-MyD88 signaling in CD8 T cell clonal expansion and memory formation following vaccinia viral infection. Blood 113:2256-2264.
37. Raki, M., A. Kanerva, A. Ristimaki, R. A. Desmond, D. T. Chen, T. Ranki, M. Sarkioja, L. Kangasniemi, and A. Hemminki. 2005. Combination of gemcitabine and Ad5/3-Δ24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Ther. 12:1198-1205.
38. Raper, S. E., N. Chirmule, F. S. Lee, N. A. Wivel, A. Bagg, G. P. Gao, J. M. Wilson, and M. L. Batshaw. 2003. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 80:148-158.
39. Sallinen, H., M. Anttila, J. Narvainen, J. Koponen, K. Hamalainen, I. Kholova, T. Heikura, P. Toivanen, V. M. Kosma, S. Heinonen, K. Alitalo, and S. Yla-Herttuala. 2009. Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice. Mol. Ther. 17:278-284.
40. Shen, Y., and J. Nemunaitis. 2005. Fighting cancer with vaccinia virus: teaching new tricks to an old dog. Mol. Ther. 11:180-195.
41. Sivanandam, V. G., S. L. Stephen, R. Hernandez-Alcoceba, P. Alzuguren, M. Zabala, N. van Rooijen, C. Qian, I. Berger, M. L. Gross, J. Prieto, and S. Kochanek. 2008. Lethality in an anti-angiogenic tumor gene therapy model upon constitutive but not inducible expression of the soluble vascular endothelial growth factor receptor 1. J. Gene Med. 10:1083-1091.
42. Thorne, S. H., D. L. Bartlett, and D. H. Kirn. 2005. The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally? Curr. Gene Ther. 5:429-443.
43. Thorne, S. H., T. H. Hwang, W. E. O'Gorman, D. L. Bartlett, S. Sei, F. Kanji, C. Brown, J. Werier, J. H. Cho, D. E. Lee, Y. Wang, J. Bell, and D. H. Kirn. 2007. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J. Clin. Investig. 117:3350-3358.
44. Tsung, K., J. H. Yim, W. Marti, R. M. Buller, and J. A. Norton. 1996. Gene expression and cytopathic effect of vaccinia virus inactivated by psoralen and long-wave UV light. J. Virol. 70:165-171.
45. Zeh, H. J., and D. L. Bartlett. 2002. Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. Cancer Gene Ther. 9:1001-1012.
46. Zhu, J., J. Martinez, X. Huang, and Y. Yang. 2007. Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta. Blood 109:619-625.
47. Zhu, X., S. Wu, W. L. Dahut, and C. R. Parikh. 2007. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am. J. Kidney Dis. 49:186-193.